HERON THERAPEUTICS, INC. annual report, FY2023

Heron Therapeutics, Inc. — FY2023 Form 10-K Summary

Business context and reporting period

Heron Therapeutics is a commercial-stage biotechnology company focused on acute-care and oncology products using its Biochronomer drug-delivery technology. This Form 10-K covers the fiscal year ended December 31, 2023; the source does not provide a separate fourth-quarter income statement.

Products: ZYNRELEF for postoperative pain; APONVIE for postoperative nausea and vomiting; CINVANTI and SUSTOL for chemotherapy-induced nausea and vomiting.
All 2023 revenue was generated in the United States and substantially all sales were made through three customers, which represented 99.1% of net product sales.
Heron had 126 full-time employees at year-end, including 72 in sales and marketing. A June 2023 restructuring reduced the workforce by approximately 25%.

Financial performance and key metrics

Metric	FY2023	FY2022	Change
Net product sales	$127.0 million	$107.7 million	18.0% increase
Gross profit	$61.9 million	$52.8 million	17.3% increase
Gross margin	48.8%	49.0%	Approximately flat
Operating expenses	$172.6 million	$227.5 million	24.1% decrease
Loss from operations	$(110.6) million	$(174.7) million	Loss narrowed
Net loss	$(110.6) million	$(182.0) million	Loss narrowed
Net loss per share	$(0.80)	$(1.67)	Improved
Cash used in operations	$(58.8) million	$(146.9) million	Use decreased
Cash, cash equivalents and short-term investments	$80.4 million	$84.9 million	5.2% decrease

Calculated operating margin was approximately (87.1%) in 2023, compared with approximately (162.3%) in 2022. Net margin was approximately (87.0%) in 2023, compared with approximately (169.1%) in 2022.

Product sales: CINVANTI $94.9 million, ZYNRELEF $17.7 million, SUSTOL $13.1 million and APONVIE $1.4 million. APONVIE launched commercially in March 2023.
Cost of product sales: $65.1 million, including $20.3 million of charges primarily related to ZYNRELEF inventory write-offs, compared with $8.9 million of such charges in 2022.
Research and development: $55.9 million, down from $107.5 million, primarily because scale-up and validation activities for ZYNRELEF and CINVANTI were substantially completed and restructuring reduced personnel costs.
General and administrative: $49.0 million, up from $37.4 million, due primarily to executive departure costs and CINVANTI patent litigation.
Sales and marketing: $67.6 million, down from $82.5 million, reflecting improved ZYNRELEF commercialization efficiencies.
Stock-based compensation: $32.9 million, down from $43.0 million.

Cash flow, liquidity and debt

Operating cash burn was $58.8 million. Investing activities provided $18.0 million, principally from $19.5 million of net maturities of short-term investments. Financing activities provided $54.1 million.
Year-end cash and cash equivalents were $28.7 million, and short-term investments were $51.7 million.
Management stated that available cash, cash equivalents and short-term investments are expected to fund anticipated requirements for at least one year from the filing date, subject to significant assumptions regarding ZYNRELEF commercialization.
$150.0 million principal amount of senior unsecured convertible notes was outstanding, carrying 1.5% annual interest and maturing May 26, 2026, unless converted, redeemed or repurchased earlier.
$25.2 million principal amount was outstanding under a working capital facility as of year-end, with stated cash interest of 9.95%, 1.5% paid-in-kind interest and a minimum cash covenant of $8.5 million if market capitalization is below $400 million. The carrying value was $24.3 million.
Purchase obligations to third-party manufacturers totaled $60.2 million, including $39.0 million due within one year. Lease obligations totaled $6.3 million.
The company ended 2023 with stockholders’ deficit of $34.0 million and an accumulated deficit of $1.906 billion.

Material changes versus the prior comparable period

Revenue increased 18%, driven by higher unit volumes for ZYNRELEF, CINVANTI and SUSTOL and the initial contribution from APONVIE.
Operating loss and net loss narrowed substantially as research and development and sales and marketing spending declined.
Gross margin was broadly stable despite higher product sales because inventory write-offs increased materially, particularly for ZYNRELEF.
Heron completed a June 2023 workforce reduction and made leadership changes. Total 2023 restructuring and executive departure costs were approximately $17.6 million, including $8.7 million of non-cash stock-based compensation.
Heron raised approximately $29.8 million net through a July 2023 private placement and received approximately $24.4 million net from the initial working-capital-facility funding.
Shares outstanding increased to 150.3 million at December 31, 2023 from 119.2 million at December 31, 2022, creating meaningful equity dilution.
The company paused development of HTX-034 while evaluating the program and market opportunity.

Guidance, outlook, risks, contingencies and unusual items

Management expects total operating expenses to decrease year over year in 2024 as a result of cost-reduction efforts, but provides no quantified revenue, earnings or cash-flow guidance.
In January 2024, Heron entered a five-year partnership with CrossLink Life Sciences to expand ZYNRELEF promotion, particularly in orthopedic indications. Approximately 650 representatives are expected to be added to the sales network; the financial impact was not yet estimable.
ZYNRELEF received a U.S. label expansion in January 2024. The company expects potential benefit from expanded indications and separate Medicare payment provisions for certain non-opioid pain products beginning in 2025, but competition could also increase.
Heron relies on a small number of third-party manufacturers, and certain critical materials are sourced from single suppliers. Manufacturing interruptions, quality issues, supply constraints or inventory obsolescence could impair sales and margins.
Commercial concentration is significant: three customers accounted for 99.1% of 2023 product sales and 99.7% of year-end accounts receivable.
Generic competition has reduced CINVANTI and SUSTOL sales historically. Patent litigation is pending against Fresenius Kabi and Mylan concerning generic CINVANTI, and against Mylan concerning generic APONVIE. A five-day CINVANTI bench trial was scheduled for June 24, 2024.
Key intellectual-property dates include U.S. SUSTOL patents expiring in September 2024, while U.S. patents covering ZYNRELEF, CINVANTI and APONVIE generally extend into the 2030s, subject to litigation and validity risks.
The company has a history of substantial losses, negative operating cash flow and dependence on additional product growth or financing. Management’s liquidity assessment depends materially on assumptions about ZYNRELEF market adoption.
The audited financial statements received an unqualified opinion, and management and the auditor concluded that internal control over financial reporting was effective as of December 31, 2023.

Most important facts for an investor to verify

Whether ZYNRELEF sales accelerate sufficiently after the 2024 label expansion and CrossLink rollout to reduce cash burn.
Actual quarterly cash burn, inventory levels and additional ZYNRELEF inventory write-offs following the $20.3 million 2023 charge.
Liquidity relative to the $60.2 million manufacturing purchase commitments, the $25.2 million working capital facility and the $150.0 million convertible notes maturing in 2026.
Results and timing of the CINVANTI and APONVIE patent litigation and the potential timing of generic competition.
The effect of the 2023 financing transactions, outstanding warrants, convertible notes and equity awards on future dilution.
Customer concentration, product-return allowances and reimbursement or pricing changes that could affect reported net sales.
Whether expense reductions are sustainable without impairing commercialization, manufacturing, regulatory compliance or product development.